Genelux Corporation (GNLX), a late clinical-stage immuno-oncology company, today announced the publication of positive topline results from its Phase 2…
Genelux Corporation (GNLX), a late clinical-stage immuno-oncology company, today announced the publication of positive topline results from its Phase 2…